Two medications now dominate the GLP-1 weight loss landscape: semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss). Both are highly effective — but they work differently, have different side effect profiles, and may suit different patients. Here's everything you need to know to make an informed decision with your provider.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — it mimics the glucagon-like peptide-1 hormone that your gut naturally produces after eating. By binding to GLP-1 receptors in the brain and digestive system, it suppresses appetite, slows gastric emptying, and helps regulate blood sugar levels. It is administered as a once-weekly subcutaneous injection.
Semaglutide was first approved by the FDA in 2017 as Ozempic for Type 2 diabetes management. In 2021, the FDA approved a higher-dose formulation — Wegovy — specifically for chronic weight management. It has one of the most extensive clinical evidence bases of any weight loss medication ever developed.
Key Clinical Data: Semaglutide
- Average weight loss: 15.3% of body weight over 68 weeks (STEP 1 trial, n=1,961)
- Over 86% of patients lost at least 5% of body weight
- Over 69% of patients lost at least 10% of body weight
- Demonstrated a 20% reduction in major cardiovascular events (SELECT trial, n=17,604)
- Once-weekly injection, 0.25mg–2.4mg dose range
💡 The SELECT cardiovascular outcomes trial — the largest GLP-1 trial ever conducted — showed semaglutide reduced the risk of heart attack, stroke, and cardiovascular death by 20% in patients with obesity and established cardiovascular disease.
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a first-of-its-kind medication that activates two hormone pathways simultaneously. In addition to mimicking GLP-1, it also mimics GIP (glucose-dependent insulinotropic polypeptide), another gut hormone involved in insulin secretion and fat metabolism. This dual mechanism produces even greater weight loss than GLP-1 activation alone.
Tirzepatide was FDA-approved as Mounjaro for Type 2 diabetes in 2022, and as Zepbound for chronic weight management in late 2023. While newer to market than semaglutide, its clinical trial results have been remarkable — and it is rapidly becoming the preferred option for many patients and providers.
Key Clinical Data: Tirzepatide
- Average weight loss: 20.9% of body weight over 72 weeks (SURMOUNT-1 trial, n=2,539)
- Over 91% of patients lost at least 5% of body weight
- Over 57% of patients lost at least 20% of body weight
- At the highest dose (15mg), average weight loss reached 22.5%
- Once-weekly injection, 2.5mg–15mg dose range
💡 In the SURMOUNT-1 trial, tirzepatide at the highest dose produced average weight loss of 22.5% — equivalent to approximately 52 lbs for a 230 lb person. This is the greatest weight loss ever demonstrated by a pharmaceutical agent in a clinical trial.
Head-to-Head: How Do They Compare?
While no large randomized controlled trial has directly compared semaglutide and tirzepatide head-to-head for weight loss specifically, observational studies and cross-trial comparisons consistently show tirzepatide producing greater weight loss. Here is a comprehensive side-by-side comparison:
| Factor | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Avg. Weight Loss | ~15% body weight | ~21% body weight Higher |
| Dosing | Once weekly injection | Once weekly injection |
| FDA Approval (Weight) | 2021 (Wegovy) | 2023 (Zepbound) |
| Cardiovascular Data | Extensive (SELECT trial) More data | Ongoing (SURMOUNT-MMO) |
| Common Side Effects | Nausea, constipation, fatigue | Nausea, diarrhea, constipation |
| List Price (monthly) | ~$1,349 | ~$1,059 Lower |
| Insurance Coverage | Broader coverage history | Growing coverage |
| Compounded Options | Available | Available |
| Long-Term Safety | Extensive multi-year data More data | 2+ years data, growing |
Side Effects: What to Expect from Each
Both medications share a similar side effect profile, as both slow gastric emptying and affect the same hormonal pathways. However, there are some nuanced differences worth knowing.
Semaglutide Side Effects
- Nausea — most common, especially during dose escalation (44% of patients)
- Constipation — reported in about 24% of patients
- Diarrhea — reported in about 30% of patients
- Vomiting — less common, typically early in treatment
- Fatigue — mild, usually resolves within weeks
Tirzepatide Side Effects
- Nausea — similar to semaglutide, reported in ~31–45% of patients
- Diarrhea — slightly more common than with semaglutide (~23–30%)
- Constipation — reported in ~17–22% of patients
- Vomiting — reported in ~8–13% of patients
- Decreased appetite — the intended effect, but can be pronounced
⚠️ Both medications carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies. They are not recommended for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always disclose your full medical history to your provider.
Who Should Choose Which Medication?
The right medication depends on your individual health profile, goals, insurance coverage, and tolerance for side effects. Here are some general guidelines — though your Healthcare One provider will make the final recommendation based on your complete medical history.
Consider Semaglutide If You:
- Have established cardiovascular disease and want the proven SELECT trial data
- Have better insurance coverage for Wegovy than Zepbound
- Prefer a medication with a longer track record and more long-term safety data
- Have previously tried tirzepatide without adequate response
- Are managing Type 2 diabetes and your endocrinologist prefers semaglutide
Consider Tirzepatide If You:
- Want the maximum possible weight loss — tirzepatide consistently outperforms semaglutide
- Have Type 2 diabetes and want superior blood sugar control alongside weight loss
- Have tried semaglutide and want to escalate to a more powerful option
- Have better insurance coverage for Zepbound or Mounjaro
- Are comfortable with a newer medication with a rapidly growing evidence base
💡 Many Healthcare One patients start with semaglutide and transition to tirzepatide after 3–6 months to accelerate results. Your provider will monitor your progress and recommend adjustments based on your response to treatment.
Cost, Insurance & Access
Cost is a significant factor for many patients. Both medications carry high list prices, but there are several pathways to make them more affordable:
- Manufacturer savings cards: Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) both offer savings programs that can reduce out-of-pocket costs significantly for eligible patients
- Insurance coverage: Coverage varies widely by plan. Some Medicare Part D plans now cover Zepbound; commercial insurance coverage for both is expanding
- Compounded medications: FDA-registered compounding pharmacies can provide semaglutide and tirzepatide at significantly lower cost — Healthcare One works with trusted compounding partners
- Prior authorization: Your Healthcare One provider will handle all prior authorization paperwork on your behalf
The Bottom Line
Both semaglutide and tirzepatide are transformative medications that have changed the landscape of obesity treatment. If your primary goal is maximum weight loss and you don't have contraindications, tirzepatide has demonstrated superior efficacy in clinical trials. If you have established cardiovascular disease and want the most robust long-term safety data, semaglutide's SELECT trial results are compelling.
The most important step is to speak with a licensed provider who can evaluate your complete health history and recommend the right medication, dose, and support plan for you. At Healthcare One, our physicians specialize in GLP-1 therapy and will guide you through every step of the process — from your initial consultation to ongoing monitoring and dose adjustments.